Anabela Bandeira

Anabela Bandeira

Auto-generated profile, based on publicly available information

Anabela Bandeira

Centro de Referência na área de Doenças Hereditárias do Metabolismo, Centro Hospitalar Universitário do Porto-CHUP, 4099-001 Porto, Portugal

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2016 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
PDF file
MHMartina Huemer
Martina Huemer
DDDaria Diodato
Daria Diodato
BSBernd Schwahn
Bernd Schwahn
MSManuel Schiff
Manuel Schiff
ABAnabela Bandeira
Anabela Bandeira
CDCarlo Dionisi-Vici
Carlo Dionisi-Vici
Background: Remethylation defects are rare inherited disorders in which impaired remethylation of homocysteine to methionine leads to accumulation of homocysteine and perturbation of numerous methylation reactions.Objective: To summarise clinical and biochemical characteristics of these severe disorders and to provide guidelines on diagnosis and management.Data sources: Review, evaluation and discussion of the medical literature (Medline, Cochrane databases) by a panel of experts on these rare diseases following the GRADE approach.Key recommendations: We strongly recommend measuring plasma total homocysteine in any patient presenting with the combination of neurological and/or visual and/or haematological symptoms, subacute spinal cord degeneration, atypical haemolytic uraemic syndrome or unexplained vascular thrombosis. We strongly recommend to initiate treatment with parenteral hydroxocobalamin without delay in any suspected remethylation disorder; it significantly improves survival and incidence of severe complications. We strongly recommend betaine treatment in individuals with MTHFR deficiency; it improves the outcome and prevents disease when given early.

21 February 2022 in Journal of Nutrition and Metabolism
Verified
Journal Article
Open access
PDF file
SMSara Mosca
Sara Mosca
GAGraça Araújo
Graça Araújo
VCVanessa Costa
Vanessa Costa
JCJoana Correia
Joana Correia
ABAnabela Bandeira
Anabela Bandeira
MCMargarida Paiva Coelho
Margarida Paiva Coelho
Dyslipidemias or dyslipoproteinemias are quantitative changes in total cholesterol concentration, respective fractions, or triglycerides in the plasma. Evidence supported that dyslipidemia in childhood is associated with atherosclerosis in adulthood, and early identification and treatment potentially reduce cardiovascular risk in adulthood, which is the principal cause of morbidity and mortality in developed countries. Dyslipidemias can result from primary lipoprotein metabolism changes due to different genetic causes (primary dyslipidemias) or as a consequence of exogenous factors or other pathologies (secondary dyslipidemias). Therefore, the combined dyslipidemias result from the association of important epigenetic and environmental influences with risk factors for cardiovascular disease. The criterion for lipid metabolism screening at young ages is not widely accepted and possibly follows a universal or directed screening strategy. Additionally, little is known about its long-term effects or possible risk-benefit despite the growing tendency to start pharmacological therapy. Therefore, this study aimed to review the available bibliography on dyslipidemia in pediatric age to present a practical and structured approach to dyslipidemia that focuses on screening, risk stratification for atherosclerotic disease, and therapeutic approach.

12 February 2018 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
TBTheodora U. J. Bruun
Theodora U. J. Bruun
SSSarah Sidky
Sarah Sidky
ABAnabela O. Bandeira
Anabela O. Bandeira
FDFrancoise-Guillaume Debray
Francoise-Guillaume Debray
CFCan Ficicioglu
Can Ficicioglu
SMSaadet Mercimek-Andrews
Saadet Mercimek-Andrews

12 April 2017 in European Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
APA Pinto
A Pinto
Manuela Ferreira de AlmeidaManuela Ferreira de Almeida
Manuela Ferreira de Almeida
PRP C Ramos
P C Ramos
SRS Rocha
S Rocha
AGA Guimas
A Guimas
Júlio César RochaJúlio César Rocha
Júlio César Rocha


30 April 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
APAlex Pinto
Alex Pinto
Manuela Ferreira de AlmeidaManuela Ferreira de Almeida
Manuela Ferreira de Almeida
Anita MacDonaldAnita MacDonald
Anita MacDonald
PRPaula Cristina Ramos
Paula Cristina Ramos
SRSara Rocha
Sara Rocha
Júlio César RochaJúlio César Rocha
Júlio César Rocha
Phenylalanine (Phe) tolerance is highly variable in phenylketonuria (PKU) and rarely described in patients aged ≥12 years. Patients ≥12 years of age with PKU were systematically challenged with additional natural protein (NP) if blood Phe levels remained below 480 µmol/L (i.e., upper target blood Phe level for patients aged ≥12 years using Portuguese PKU guidelines). In PKU patients, NP tolerance was calculated at baseline and a median of 6 months after systematic challenge with NP whilst patients were maintaining a blood Phe ≤480 μmol/L. Anthropometry was assessed at both times. Routine blood Phe levels were collected. We studied 40 well-controlled PKU patients (10 hyperphenylalaninemia (HPA), 23 mild and 7 classic PKU), on a low-Phe diet with a mean age of 17 years (12–29 years). Median daily NP intake significantly increased between assessments (35 vs. 40 g/day, p = 0.01). Twenty-six patients (65%) were able to increase their median NP intake by a median 12 g/day (2–42 g)/day and still maintain blood Phe within target range. Out of the previous 26 patients, 20 (77%) (8 HPA, 11 mild and 1 classical PKU) increased NP from animal sources (e.g., dairy products, fish and meat) and 6 patients (23%) (3 mild and 3 classical PKU) from plant foods (bread, pasta, potatoes). Median protein equivalent intake from Phe-free/low-Phe protein substitute decreased (0.82 vs. 0.75 g/kg, p = 0.01), while median blood Phe levels remained unchanged (279 vs. 288 μmol/L, p = 0.06). Almost two-thirds of patients with PKU tolerated additional NP when challenged and still maintained blood Phe within the national target range. This suggests that some patients with PKU treated by a low-Phe diet only may over restrict their NP intake. In order to minimise the burden of treatment and optimise NP intake, it is important to challenge with additional NP at periodic intervals.